These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9556783)

  • 21. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. XELOX in colorectal cancer: a convenient option for the future?
    Lindsay CR; Cassidy J
    Expert Rev Gastroenterol Hepatol; 2011 Feb; 5(1):9-19. PubMed ID: 21309667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant therapy for breast cancer.
    Hennessy BT; Pusztai L
    Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A pilot study of combination chemotherapy with cyclophosphamide, adriamycin, chronic daily dosing of oral etoposide for patients with SCLC ineligible for intensive chemotherapy].
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Gan To Kagaku Ryoho; 1995 Feb; 22(3):389-93. PubMed ID: 7880110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Progress in oral anti-cancer drug therapy for urological cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):308-14. PubMed ID: 10065093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
    Kimura M; Sasagawa T; Tomita Y; Katagiri A; Morishita H; Saito T; Tanikawa T; Kawasaki T; Saito K; Nishiyama T; Kasahara T; Hara N; Takahashi K
    Hinyokika Kiyo; 2003 Dec; 49(12):709-14. PubMed ID: 14978952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical trial of oral etoposide in the treatment of malignancies].
    Zhang X; Zhu H; Xu J
    Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):454-7. PubMed ID: 8698002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral blood progenitor cell mobilisation in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy.
    Cook G; Marinaki P; Farrell E; Pearson C; Alcorn MJ; Sharp RA; Tansey PJ; Franklin IM
    Leukemia; 1997 Dec; 11 Suppl 5():S35-40. PubMed ID: 9436937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.
    Grunberg SM; Crowley J; Hande KR; Giroux D; Munshi N; Lau DH; Schroder LE; Zangmeister MH; Balcerzak SP; Hynes HE; Gandara DR
    Cancer Chemother Pharmacol; 1999; 44(6):461-8. PubMed ID: 10550566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral 5-FU alternatives for the treatment of head and neck cancer.
    Vokes EE; Brockstein BE; Humerickhouse R; Haraf DJ
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):35-8. PubMed ID: 9830623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
    Skirvin JA; Lichtman SM
    Drugs Aging; 2002; 19(1):25-42. PubMed ID: 11929325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral cancer chemotherapy in paediatric patients: obstacles and potential for development and utilisation.
    Bleyer WA; Danielson MG
    Drugs; 1999; 58 Suppl 3():133-40. PubMed ID: 10711852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of the changing paradigm in cancer treatment: oral chemotherapy.
    Aisner J
    Am J Health Syst Pharm; 2007 May; 64(9 Suppl 5):S4-7. PubMed ID: 17468157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology of antineoplastic agents in older cancer patients.
    Lichtman SM; Skirvin JA; Vemulapalli S
    Crit Rev Oncol Hematol; 2003 May; 46(2):101-14. PubMed ID: 12711355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral antineoplastics in nononcology units: moving toward safer ordering, administration, and handling.
    Leifeste K
    Clin J Oncol Nurs; 2014 Aug; 18(4):411-3. PubMed ID: 25095293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.